Clinical Trial

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

Study acronym: STARLIGHT
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this study is to assess the safety and efficacy of GSK4532990 in participants with alcohol-related liver disease.
Protocol Amendment History 4 changes
notable Trial sites expanded: 131 -> 140 locations 2026-08-04
notable Primary completion pushed: 2027-08-02 -> 2027-11-26 2026-08-04
critical Primary endpoint(s) modified 2026-04-02
notable Trial sites expanded: 123 -> 131 locations 2026-04-02
Trial Details
NCT Number NCT06613698
Lead Sponsor GlaxoSmithKline
Conditions Liver Diseases, Alcoholic
Enrollment 393 participants
Start Date 2024-09-27
Primary Completion 2027-11-26 (estimated)
Study Completion 2028-03-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-03